KeyCorp Comments on Alpha Teknova, Inc.’s Q2 2023 Earnings (NASDAQ:TKNO)

Posted by Defense World Staff on Jul 16th, 2023

Alpha Teknova, Inc. (NASDAQ:TKNO – Free Report) – Analysts at KeyCorp issued their Q2 2023 EPS estimates for Alpha Teknova in a report released on Tuesday, July 11th. KeyCorp analyst P. Knight expects that the company will post earnings of ($0.26) per share for the quarter. KeyCorp has a “Sector Weight” rating on the stock. The consensus estimate for Alpha Teknova’s current full-year earnings is ($1.07) per share. KeyCorp also issued estimates for Alpha Teknova’s Q3 2023 earnings at ($0.23) EPS, Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($1.00) EPS, FY2024 earnings at ($0.71) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at $0.45 EPS.

Alpha Teknova Price Performance

NASDAQ TKNO opened at $3.52 on Friday. The company has a current ratio of 5.74, a quick ratio of 4.33 and a debt-to-equity ratio of 0.24. Alpha Teknova has a 1 year low of $1.62 and a 1 year high of $8.25. The company has a market cap of $99.34 million, a PE ratio of -1.96 and a beta of -0.14. The stock’s 50-day moving average price is $3.00 and its two-hundred day moving average price is $3.83.

Alpha Teknova (NASDAQ:TKNO – Get Free Report) last announced its earnings results on Wednesday, May 10th. The company reported ($0.31) earnings per share (EPS) for the quarter. Alpha Teknova had a negative return on equity of 31.25% and a negative net margin of 128.92%. The company had revenue of $9.12 million for the quarter, compared to analyst estimates of $7.80 million.

Insider Transactions at Alpha Teknova

In other Alpha Teknova news, insider Lisa Hood sold 11,400 shares of the business’s stock in a transaction on Tuesday, June 13th. The shares were sold at an average price of $3.80, for a total transaction of $43,320.00. Following the sale, the insider now directly owns 33,834 shares of the company’s stock, valued at approximately $128,569.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have bought a total of 10,580 shares of company stock valued at $20,749 over the last ninety days. Corporate insiders own 17.20% of the company’s stock.

Hedge Funds Weigh In On Alpha Teknova

A number of large investors have recently made changes to their positions in TKNO. JPMorgan Chase & Co. grew its position in Alpha Teknova by 27.9% during the first quarter. JPMorgan Chase & Co. now owns 6,571 shares of the company’s stock valued at $91,000 after purchasing an additional 1,435 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Alpha Teknova in the first quarter worth $145,000. Dimensional Fund Advisors LP purchased a new stake in shares of Alpha Teknova during the third quarter worth $36,000. Tower Research Capital LLC TRC raised its holdings in shares of Alpha Teknova by 825.7% during the third quarter. Tower Research Capital LLC TRC now owns 12,154 shares of the company’s stock worth $40,000 after acquiring an additional 10,841 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in Alpha Teknova during the second quarter valued at $175,000. Institutional investors and hedge funds own 19.57% of the company’s stock.

Alpha Teknova Company Profile

(Get Free Report)

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.